Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Drugs Dermatol ; 21(10): 1098-1103, 2022 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-36219052

RESUMEN

BACKGROUND: Acne vulgaris has a multifactorial pathogenesis, and combination therapy is recommended in most patients. A tretinoin 0.1%/benzoyl peroxide 3% (Tret-BPO) cream which uses a core-shell encapsulation system to enhance the stability of both active ingredients recently received approval from the Food and Drug Administration (FDA). OBJECTIVE: To review the pharmacokinetics, efficacy, and safety of recently approved Tret-BPO. METHODS: A review of literature was conducted using the EMBASE, MEDLINE (Pubmed), and Clinicaltrials.gov databases in December 2021. Articles in English discussing the use of Tret-BPO in the treatment of acne vulgaris were included. RESULTS: In a phase 2 trial, Tret-BPO achieved Investigators Global Assessment (IGA) success more often (39.7%) than vehicle (12.3%; P<0.001). In 2 phase 3 trials, Tret-BPO had a higher success rate (Trial 1: 38.5% and Trial 2: 25.4%) when compared with vehicle (Trial 1: 11.5% and Trial 2: 14.7%; P<0.001 and P=0.017). LIMITATION: This review was limited by the lack of clinical trials assessing the efficacy and safety of Tret-BPO compared with other acne treatments. CONCLUSIONS: Tret-BPO is a safe and effective novel therapy for acne vulgaris. Poor adherence is a major hurdle in management; the combination of two separate first-line drugs may address this hurdle by decreasing the complexity of treatment regimens. J Drugs Dermatol. 2022;21(10):1098-1103. doi:10.36849/JDD.6808.


Asunto(s)
Acné Vulgar , Fármacos Dermatológicos , Acné Vulgar/inducido químicamente , Acné Vulgar/diagnóstico , Acné Vulgar/tratamiento farmacológico , Adapaleno , Peróxido de Benzoílo/efectos adversos , Fármacos Dermatológicos/efectos adversos , Método Doble Ciego , Combinación de Medicamentos , Geles/uso terapéutico , Humanos , Inmunoglobulina A/uso terapéutico , Resultado del Tratamiento , Tretinoina/efectos adversos
2.
Cureus ; 13(9): e18102, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34692313

RESUMEN

Public health efforts over the past few months have been aimed at vaccinating young adults. Moderna and Pfizer COVID-19 vaccines are widely available options. Cutaneous reactions to these vaccines have been described as self-limiting and relatively immediate after vaccine administration. In this case report, we present a young adult who received the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine and developed chronic, spontaneous urticaria.

3.
J Food Sci ; 84(8): 2357-2363, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31364176

RESUMEN

Peanut allergic consumers rely on food package labels to avoid foods containing peanut. The inadvertent presence of peanut in foods due to cross-contact can be fatal if ingestion of such food leads to an allergic reaction. Analytical methods are available to detect undeclared peanut in foods. However, depending on the type of food matrix and food processing parameters, method performance can be adversely affected due to reduction in the extraction efficiency of peanut proteins. Temperature and probe sonication were used as a preincubation treatment for peanut flour slurries to assess their effect on the total peanut protein solubility from raw, light-roasted, and dark-roasted peanut flours. The effect of these treatments on the immunoreactivity of peanut allergens (Ara h 1, Ara h 2, Ara h 3, and Ara h 6) was determined by an indirect enzyme-linked immunosorbent assay using antibodies raised against these individual peanut proteins. Preincubation at 50 °C did not significantly improve the peanut protein solubility, whereas an increase in protein solubility was observed when light- and dark-roasted peanut flour slurries were preincubated at 90 °C or sonicated. The immunoreactivity of peanut allergens varied depending on the degree of peanut flour roasting and type of preincubation treatment. Overall, the immunoreactivity of peanut allergens from most peanut flour slurries was unaffected when preincubated at 50 °C for up to 60 min or sonicated with a probe for up to 5 min, whereas preincubation at 90 °C resulted in a time-dependent reduction in immunoreactivity of peanut allergens. Sonication treatment may improve peanut protein extraction without markedly affecting their immunoreactivity. PRACTICAL APPLICATION: Extraction of peanut proteins is vital for developed analytical methods to estimate peanut allergens in foods. The manuscript describes the effect of two different temperatures (50 and 90 °C) and probe-type sonication on peanut protein solubility. The findings suggest sonication can improve peanut protein solubility without markedly affecting their immunoreactivity.


Asunto(s)
Arachis/inmunología , Antígenos de Plantas/análisis , Antígenos de Plantas/inmunología , Antígenos de Plantas/aislamiento & purificación , Arachis/química , Ensayo de Inmunoadsorción Enzimática , Harina/análisis , Manipulación de Alimentos , Humanos , Proteínas de Plantas/análisis , Proteínas de Plantas/inmunología , Proteínas de Plantas/aislamiento & purificación , Temperatura
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...